Working… Menu

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00761371
Recruitment Status : Completed
First Posted : September 29, 2008
Last Update Posted : April 10, 2015
Information provided by:
MEDA Pharma GmbH & Co. KG

Brief Summary:
Imiquimod 5% cream in the treatment of external genital or perianal warts in HIV+ patients

Condition or disease Intervention/treatment Phase
Warts Drug: Imiquimod 5% cream Phase 4

Detailed Description:
To evaluate the percentage of HIV+ subjects successfully treated with HAART, with total clearance (100%) of baseline external genital or perianal warts within 16 weeks of treatment with imiquimod 5% cream.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Exploratory Evaluation of Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Treated With HAART (CD4+ ≥ 200 Cells mm3): An Open Labeled, Non-comparative Study
Study Start Date : August 2002
Actual Primary Completion Date : February 2004
Actual Study Completion Date : February 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS Warts
Drug Information available for: Imiquimod

Arm Intervention/treatment
Experimental: Imiquimod
Imiquimod 5% cream
Drug: Imiquimod 5% cream
Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.

Primary Outcome Measures :
  1. The percentage of subjects with total clearance of initially treated external genital or perianal warts. [ Time Frame: week 16 ]

Secondary Outcome Measures :
  1. Total clearance [ Time Frame: week 16 ]
  2. Percentage of subjects with a partial reduction of initial wart area; [ Time Frame: week 16 ]
  3. Time to achieve reduction in wart area; [ Time Frame: week 16 ]
  4. Reduction in wart number [ Time Frame: week 16 ]
  5. Appearance of new warts [ Time Frame: week 16 ]
  6. Recurrence rate [ Time Frame: week 16 ]
  7. HPV DNA [ Time Frame: week 16 ]
  8. CD4+ lymphocyte and HIV RNA levels [ Time Frame: week 16 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject able to understand and willing to give written informed consent.
  2. Subject ≥ 18 and < 70 years of age.
  3. Male or female with an HIV infection documented by serology (enzyme linked immunoabsorbent assay (ELISA)), Western Blot assay, or HIV viral load.
  4. Treated with HAART for at least six months and compliant with the treatment.
  5. Evidence of efficacy of HAART: total CD4+ lymphocyte counts of ≥ 200 cells/mm3 AND plasma HIV RNA level < 104 RNA copies/mL within four weeks prior to the Treatment Initiation Visit.
  6. Presence of at least one visible genital or perianal wart as determined by clinical diagnosis.
  7. Total wart area > 10 mm2 and ≤ 4000 mm2 (diameter > 0.4 cm and ≤ 7.1 cm)
  8. Karnofsky Performance Status ≥ 70 %.
  9. Accepting to abstain from sexual intercourse when study drug is on the skin.
  10. In case of a coexisting AIDS-defining illness, both this illness and any treatment being received for it must have been stable for the four weeks preceding enrolment in the trial.
  11. If female and of childbearing potential, have negative urine pregnancy tests, and willing to use a medically acceptable method of contraception during the 16-week treatment period. Subjects were considered to be of childbearing potential unless the uterus or both ovaries had been removed or they were two or more years postmenopausal. For this study, the following were considered to be acceptable methods of contraception:

    • Surgical sterilization, defined as tubal ligation of the subject or a vasectomy of the subject's partner if that subject is in a monogamous heterosexual relationship (at the Investigator's discretion)
    • Oral, injectable, or implantable contraceptives
    • Condoms (with spermicide)
    • Diaphragm/cervical cap (with spermicide)
    • Intrauterine devices (IUDs)
    • Complete abstinence (at the Investigator's discretion)

Exclusion Criteria:

  1. Women pregnant or lactating;
  2. Treatment within four weeks prior to the Treatment Initiation Visit and throughout the entire study with:

    • Any genital wart therapy, or Immunomodulators
    • Systemic antiviral drugs other than acyclovir, valacyclovir, or famcyclovir and other than HAART

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00761371

Layout table for location information
Départment de Gynécologie-Obstétrique CHU Saint-Pierre
Brussels, Belgium, B-1000
Service de Dermatologie CHU Saint-Pierre
Brussels, Belgium, B-1000
Service Dermatologie C.H. François Rabelais (César de Paepe)
Brussels, Belgium, B-1000
Service de Dermatologie Hôpital Erasme
Brussels, Belgium, B-1070
Service de Dermatologie et Vénéréologie Hôpital Saint Jacques
Besancon Cedex, France, F-25030
Cabinet Médical
Bordeaux, France, F-33800
Service de Dermatologie, Hôpital Ambroise Paré
Boulogne Billancourt, France, F-92100
Service de Maladies Infectieuses Hôpital de la Conception
Marseille, France, F-13005
Service de Dermatologie Hôtel Dieu
Nantes, France, F-44000
Service de Dermatologie Hôpital de l'Archet II
Nice, France, F-06202
Service Dermatologie Hopital COCHIN - Pavillon Tarnier
Paris, France, F-75006
Cabinet Médical
Paris, France, F-75011
Institut Alfred Fournier
Paris, France, F-75014
Cabinet Médical
Paris, France, F-75015
Service de Dermatologie Groupe Hospitalier Bichat Claude Bernard
Paris, France, F-75018
Service de Dermatologie Hopital Tenon
Paris, France, F-75020
Service de Dermatologie Groupe Hospitalier La Grave
Toulouse, France, F-31052
Service de Dermatologie Centre Hospitalier de Valence
Valence, France, F-26000
Sponsors and Collaborators
MEDA Pharma GmbH & Co. KG
Layout table for investigator information
Principal Investigator: Philippe Saiag, MD, Prof. Hospital Ambroise Pare, Department of Dermatology

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Joachim Maus, MD / Director, Clinical Development, Meda Pharma GmbH & Co. KG Identifier: NCT00761371     History of Changes
Other Study ID Numbers: 1456-IMIQ
First Posted: September 29, 2008    Key Record Dates
Last Update Posted: April 10, 2015
Last Verified: April 2015
Keywords provided by MEDA Pharma GmbH & Co. KG:
external genital and perianal warts
Additional relevant MeSH terms:
Layout table for MeSH terms
Papillomavirus Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Tumor Virus Infections
Skin Diseases, Infectious
Skin Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers